CS
VTGN icon

Credit Suisse’s VistaGen Therapeutics VTGN Stock Holding History

Credit Suisse’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Hold
0
– -$1 – 3743
2022
Q4 		– Sell
-76
Closed -$286 – 3923
2022
Q3 		$0 Buy
76
+73
+2,433% +$724 ﹤0.01% 4325
2022
Q2 		$0 Buy
+3
New +$106 ﹤0.01% 4356

Other funds holding VTGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Credit Suisse's VTGN Position: Q1 2023 in Review

Credit Suisse held its VistaGen Therapeutics (VTGN) position steady in Q1 2023 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #3743.

Credit Suisse first reported a position in VTGN in Q2 2022 and has held it in 2 quarters since. The position peaked at $0 in Q3 2022. 83 funds tracked by Wall St. Rank hold VTGN as of Q1 2023.

  • Credit Suisse held 0 shares of VistaGen Therapeutics worth $0 as of Q1 2023.
  • Credit Suisse left its VistaGen Therapeutics share count unchanged in Q1 2023.
  • VistaGen Therapeutics made up ﹤0.01% of Credit Suisse's portfolio in Q1 2023, its #3743 holding.
  • Credit Suisse first reported a position in VistaGen Therapeutics in Q2 2022 and has held it in 2 quarters since.
  • Credit Suisse's VistaGen Therapeutics position peaked at $0 in Q3 2022.
  • 83 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q1 2023.

Based on Credit Suisse's 13F filing for Q1 2023, filed 10 May 2023.